Microser

Quick links to important sections

Microser

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Microser

Property Description
Active ingredient Betahistine
Form Oral Tablet
Pharmacological class Antivertigo Agent (Histamine Analogue)
General purpose Relief of dizziness and vertigo symptoms
Origin Synthetic

Identity and Classification

Microser is a specialized, synthetic pharmaceutical preparation defined by its active ingredient, Betahistine (INN). It is primarily classified as an antivertigo agent (N07CA01) and chemically belongs to the class of histamine analogues. The medicine is typically dispensed as a prescription-only drug, which distinguishes it from over-the-counter remedies and indicates its intended use for medically diagnosed vestibular conditions. The drug is consistently provided in the dosage form of an Oral Tablet suitable for oral administration.

Composition and General Benefit

Microser is a single-component drug, formulated with a salt of the active substance, such as Betahistine Dihydrochloride, alongside standard inactive excipients. This composition focuses its activity on supporting the vestibular system. The pharmacological mechanism involves acting as a weak agonist at the H1-receptor and a potent antagonist at the H3-receptor.

The general purpose of Microser is to help relieve symptoms like frequent and severe dizziness and the sensation of spinning known as vertigo. This relief is provided by supporting the brain's natural ability to compensate for balance disturbances, a process known as vestibular compensation, thereby stabilizing the inner ear environment.

Regulatory References

  1. World Health Organization

What side effects are possible with Microser?

Possible Side Effects and Safety Information

The officially documented safety profile of Microser (betahistine) is structured around frequency classifications and the specific body systems affected, as reported in regulatory documents.

Adverse reactions are classified into categories such as Common and those with Not Known frequency, with the latter primarily derived from post-marketing reports. The most frequently reported adverse events in clinical trials fall under the Nervous System and Gastrointestinal Disorders.

Frequency System Organ Class Adverse Reactions
Common Nervous System Disorders Headache
Common Gastrointestinal Disorders Nausea, Dyspepsia (Indigestion)
Not Known Gastrointestinal Disorders Mild gastric complaints (e.g., vomiting, abdominal pain, bloating)
Not Known Immune System Disorders Hypersensitivity reactions (including Anaphylaxis)
Not Known Skin/Subcutaneous Tissue Disorders Cutaneous reactions (e.g., Urticaria, Angioneurotic Oedema)

Serious adverse reactions, classified as Not Known frequency, include severe Hypersensitivity Reactions such as Anaphylaxis and Angioneurotic Oedema. The occurrence of mild gastrointestinal complaints is officially noted as typically manageable by administering the dose during a meal.

Population and Safety Constraints

The medication's use is subject to specific safety constraints documented in the prescribing information. Microser is Contraindicated in individuals with phaeochromocytoma. Caution is advised for patients with a history of peptic ulceration, bronchial asthma, and existing conditions such as severe hypotension.

Furthermore, regulatory authorities state that Microser is Not Recommended for use in the paediatric population (under 18 years) due to a lack of sufficient data on safety and efficacy in this age group. No specific dose adjustment is generally required for elderly patients or those with renal or hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help

This information is based strictly on the official overdose profile documented in government regulatory sources for Microser (Betahistine).

Documented Manifestations and Severity

Official labeling describes a range of overdose presentations. Mild to moderate symptoms documented in cases up to 640 mg include nausea, somnolence (drowsiness), abdominal pain, vomiting, dyspepsia (indigestion), and ataxia. More serious, potentially life-threatening complications, such as convulsions (seizures), pulmonary complications, and cardiac complications, have been noted, particularly in cases of intentional overdose in combination with other drugs.

Severity Category Documented Manifestations
Mild to Moderate Nausea, Somnolence, Abdominal Pain, Vomiting, Ataxia
Serious Complications Convulsions, Cardiac Complications, Pulmonary Complications

Required Emergency Actions

The regulatory profile mandates immediate action for any suspected overdose. You must contact your doctor, pharmacist, a hospital emergency department, or the nearest Poison Control Centre immediately, even if the individual appears to be without discomfort or symptoms.

Management and Antidote Status

There is no specific antidote for a Microser overdose. Treatment is focused on general supportive measures and symptomatic treatment. Specific procedural steps described in official regulatory information include gastric lavage and the administration of activated charcoal, with emphasis on these interventions occurring early after intake.

Therapeutic Uses of Microser

Quick Facts

  • Indicated for the management of Ménière's disease.
  • Used to support the reduction of vertigo episodes.
  • May contribute to the lessening of tinnitus (ringing in the ears).
  • Part of a comprehensive strategy to address associated hearing loss.

What Microser treats: main uses and benefits

Microser (betahistine) is a medication indicated for the management of symptoms associated with Ménière's disease. This condition of the inner ear may present with a collection of symptoms that affect balance and hearing. Treatment with Microser is a supportive component of a patient’s overall care plan, intended to provide symptom relief.

Clinical observations suggest the medication may help in the reduction of the frequency and severity of vertigo, which involves episodes of intense dizziness and spinning sensations. It is also used to help address the presentation of tinnitus, which is the perception of ringing or buzzing in the ears. Additionally, Microser may be prescribed to support the management of progressive hearing loss and nausea associated with this inner ear condition. The therapeutic role of this agent is focused on maintaining the patient's equilibrium and influencing the symptoms of this specific disorder. Treatment goals center on symptom reduction and improving patient comfort.

Eligibility and Restrictions for Use

Microser (Betahistine) is indicated for use primarily in adults aged 18 years and older, including the elderly population. Official regulatory documents define clear exclusions and restrictions for other patient groups.

Absolute Prohibitions (Contraindications)

Use of Microser is strictly contraindicated and must be avoided in patients who have a known hypersensitivity to the active substance or any excipients. It is also prohibited for individuals with phaeochromocytoma, which is a tumor of the adrenal gland.

Populations Requiring Conditional Use or Exclusion

  • Age: The medicine is not recommended for children and adolescents under 18 years due to insufficient data on safety and efficacy in these groups.
  • Pregnancy and Lactation: Use is generally not recommended during pregnancy and breastfeeding as safety has not been established.
  • Comorbidities: Patients with bronchial asthma or a history of peptic ulceration require careful monitoring during treatment.
  • Organ Function: For patients with hepatic or renal impairment, regulatory guidance notes that no dose adjustment appears necessary, though specific clinical trials are lacking.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Microser is structured around pharmacokinetic and pharmacodynamic constraints with other substance classes.

Drug-Drug and Metabolic Interactions

Monoamine Oxidase Inhibitors (MAOIs), including the MAO-B selective inhibitor Selegiline, are associated with a documented metabolic interaction. In vitro data indicate these substances inhibit the metabolism of Betahistine, which is classified as a pharmacokinetic effect that may lead to an increase in the product’s systemic exposure.

Pharmacodynamic and Absorption Restrictions

Co-administration with Antihistamines (H1-antagonists) is expected to result in a mutual attenuation of effect due to the confirmed pharmacodynamic conflict. Some regulatory labeling advises that this combination should not be used. The official profile also documents that the administration of the product with food modifies its absorption profile by slowing the rate and reducing the peak plasma concentration (Cmax); the total extent of absorption (AUC) remains unaffected. No specific interactions with alcohol or herbal products, nor any mandatory dose separation requirements, are explicitly documented in official labeling.

Mechanism of Action

Microser functions as a dual-target modulator, primarily influencing the balance of bone remodeling cells. The mechanism involves two distinct, yet functionally integrated, molecular interactions. First, Microser acts as an inhibitor of the Glycogen Synthase Kinase-3 Beta ( GSK-3beta) enzyme, a serine/threonine protein kinase involved in cellular fate and proliferation. Inhibition of GSK-3beta disrupts the downstream signaling required for the differentiation and activity of osteoclasts. Second, Microser selectively binds to the Sirtuin 1 and 2 ( SIRT1/2) receptors. This interaction enhances the commitment and differentiation of osteoblast precursor cells into mature, functioning osteoblasts. The resulting dual action concurrently downregulates osteoclastogenesis and upregulates osteoblast activity through a common, integrated pathway cascade, leading to the modulation of overall cellular equilibrium in the bone microenvironment.

Dosage and Administration Information

Administration and Dosage Instructions

Microser (betahistine) is an oral medication, provided in tablet form, with specific instructions for administration. These instructions standardize the correct use of the medicine.


Administration Scope Standard Specifications
Route and Method Swallow the tablets whole with water. Tablets must be taken with or after a meal.
Dosing Schedule (Adults) The typical initial daily dose is 24 mg (e.g., 8 mg three times daily or 12 mg twice daily).
Maximum Daily Dose The dose may be adjusted by a healthcare professional, with the usual range being 24 –48 mg daily, not to exceed 48 mg.
Frequency Pattern The total daily dose is typically given in two or three divided doses throughout the day.
Age-Group Rule Use in children and adolescents below 18 years of age is not recommended due to a lack of data on safety and efficacy.
Missed Dose Rule If a dose is forgotten, skip the missed dose. The next dose should be taken at the usual time; do not take a double dose to compensate.

The prescribing information notes that improvement in the patient's condition may only be observed after a couple of weeks of use, and the best results are sometimes obtained after a few months. This guidance establishes a procedural structure for usage that requires consistent, long-term administration at the prescribed, divided dose, defining how the drug must be ingested in relation to food and what action to take if a scheduled dose is missed.

Recent Clinical Evidence

Microser: Recent Clinical Evidence

Evidence for use in Ménière's Disease Symptoms

Research exploring Microser was studied for symptoms associated with Ménière's disease has primarily involved Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in adults diagnosed with definite Ménière's disease. Researchers examined outcomes related to physical discomfort, such as the frequency and severity of vertigo attacks, and changes in related symptoms like tinnitus and associated hearing loss.

The overall quality of evidence has been characterized by scientific reviews as varied. Some older trials described patterns related to changes measured in vertigo endpoints; however, more recent trials reported findings were mixed concerning the measured vertigo attack frequency when compared to a placebo. Long-term effects are not fully established, and evidence is limited regarding the durability of any symptom changes over many years.


Evidence for use in Peripheral Vestibular Vertigo

Research for Microser was studied for peripheral vestibular vertigo has been evaluated in short-term Randomized Controlled Trials (RCTs). These studies typically explored short-term symptom changes in adults presenting with temporary physiological imbalance. The trials focused on outcomes related to systemic or functional imbalance, such as the measurement of dizziness symptoms and changes in patient-reported outcomes.

Scientific reviews consistently highlight that the available evidence is limited for this indication. This is often due to the short duration of the follow-up periods and the high degree of variability in participant diagnoses within these trials. Comparative evidence against other interventions remains a focus of research, and further studies are ongoing.

Key Studies & References Public Assessment Report Scientific discussion Betahistine 2Hcl Accord 24 mg, tablets (betahistine dihydrochloride)

Frequently Asked Questions (FAQ)

Common questions about Microser (FAQ)

Q: Can Microser cause drowsiness or make me feel tired?

A: Official reports from post-marketing experience indicate that Microser's active ingredient, betahistine, has been associated with effects such as tiredness (fatigue) and somnolence (drowsiness). While generally not listed as common side effects in the main clinical trials, these effects are documented in the comprehensive regulatory safety profile.

Q: Does Microser have an effect on my ability to drive or operate machinery?

A: Official labeling generally states that Microser is not likely to impair the ability to drive or operate machinery. However, the condition the medicine treats, such as vertigo or dizziness, can itself affect these abilities. Awareness of how the medicine affects an individual is noted before engaging in activities that require focus.

Q: Are there any known interactions between Microser and common supplements like vitamins?

A: Official regulatory information focuses primarily on drug-drug interactions, but typically advises that individuals inform their healthcare provider about all products they are taking, including vitamins and general supplements. Insufficient data is available to confirm the safety of combining Microser with every herbal remedy, vitamin, or dietary supplement.

Q: Do older adults typically need a different dose of Microser than younger adults?

A: According to official product information, Microser is used in the elderly population. Regulatory guidance indicates that no specific dose adjustment is generally required for patients based on age alone.

Q: How long does the effect of one dose of Microser typically last?

A: The active ingredient in Microser is rapidly absorbed and metabolized by the body. Pharmacokinetic studies show that the medicine's main metabolite reaches its peak concentration within about one hour and has a relatively short half-life of approximately 3.5 hours.

Q: Is there any risk of becoming dependent on Microser?

A: Official patient information and regulatory safety reviews indicate that there is no evidence to suggest that the medicine is addictive or carries a potential for dependence or abuse.

Q: Can Microser affect my mood or energy levels?

A: The list of adverse effects documented in official safety profiles includes tiredness (fatigue) and somnolence (drowsiness) under nervous system disorders. Specific changes to mood or other energy levels beyond general tiredness are not typically listed as common side effects.

Q: Is it common for people to gain weight while taking Microser?

A: According to the officially documented safety profile, weight gain is not listed as a common, uncommon, or rare adverse reaction of Microser from reported clinical trials and post-marketing surveillance.

Q: Can women who are planning to become pregnant use Microser?

A: Official regulatory documents advise that if a woman is pregnant or actively planning to become pregnant, the use of Microser is generally not recommended. This is typically due to a lack of established safety data for this specific patient group.

Q: Is Microser a medicine that I will need to take long-term?

A: Official prescribing information notes that treatment may require consistent, long-term administration. Evidence indicates that the best results for the condition being treated are sometimes obtained only after a few months of continuous use.

Q: What is the usual duration of a Microser treatment course?

A: There is no standard fixed duration for Microser treatment, as it is often individualized. Regulatory information indicates that noticeable improvement may take a couple of weeks, with optimal benefits sometimes taking several months.

Q: Is Microser available as a generic medicine?

A: Yes, Microser is a brand name. The medicine's active ingredient is Betahistine, which is widely available and registered under many different generic product names in various countries.

Q: Is the 'Microser' name a brand name or a common name for the drug?

A: The name Microser is a brand name or trade name. The common name for the drug, which refers to the active substance itself, is Betahistine.

Q: Does Microser have any known long-term effects on the body?

A: Official safety reviews generally describe Microser as having a good long-term safety profile with minimal serious adverse effects over extended periods. However, evidence regarding the durability of effectiveness over many years is noted as limited.

Q: Is there a specific time of day that Microser is generally recommended to be taken?

A: The total daily dose of Microser is typically divided into two or three separate doses to be taken throughout the day. It is generally recommended to take the doses at the same times each day to aid in consistent administration.

Q: Is Microser approved for treating conditions other than [main condition]?

A: Regulatory authorities have officially approved Microser for the relief of symptoms associated with Ménière's disease and related issues like peripheral vestibular vertigo. Discussions of any other uses are not present in official labeling.

Q: Does taking Microser require any special monitoring or regular blood tests?

A: Official patient information advises that a doctor may perform tests from time to time to check a patient's progress. While no mandatory regular blood tests are typically noted in general guidance, any required clinical monitoring is determined on an individual basis by a healthcare professional.

Q: Why do I need a prescription to get Microser?

A: Microser is officially classified as a prescription-only medicine in most countries. This designation is given because the medication is intended to treat a specific, medically diagnosed vestibular condition and requires proper clinical oversight.

Q: Does Microser carry any 'Black Box' or serious warnings in the US?

A: The active ingredient, betahistine, is not currently approved for use by the Food and Drug Administration (FDA) in the United States. Therefore, the product does not carry a U.S. Boxed Warning (often called a 'Black Box' warning).

Q: Can Microser interact with herbal remedies?

A: Official regulatory warnings caution that information is often not sufficient to confirm the safety of combining Microser with herbal remedies or complementary medicines. These products are generally not subject to the same rigorous testing for drug interactions as prescribed medications.

Q: Can I use Microser if I have a history of [common condition, e.g., high blood pressure]?

A: Regulatory labels advise that caution should be exercised when Microser is used in patients with certain pre-existing conditions. These include a history of severe hypotension (very low blood pressure), bronchial asthma, or a history of peptic ulceration.

Q: Why do some official drug documents list so many potential side effects for Microser?

A: The comprehensive listing of adverse reactions is a regulatory requirement. Official documents list effects based on their frequency of reporting in large-scale clinical trials and during ongoing post-marketing surveillance to ensure users are informed of all possible reported effects.

Q: What is the difference between Microser and a placebo in clinical trials?

A: A placebo is an inactive substance used in clinical trials as a control to determine the true effect of a medicine. Official study summaries describe Microser's effects on symptoms when compared to the changes experienced by participants who received the inactive placebo.

Q: Does Microser interact with cold or flu medicines?

A: Yes, there is a documented potential interaction. Many cold and flu remedies contain antihistamines, and regulatory warnings state that combining Microser with antihistamines is expected to lead to a mutual reduction (attenuation) of the expected effects of both drugs.

Q: Why is Microser considered a controlled substance (if applicable)?

A: Microser (Betahistine) is not classified as a controlled substance in major regulatory jurisdictions. Controlled substances are drugs subject to specific government scheduling controls due to their potential for abuse or dependence, which does not apply to this medicine.

Q: Is Microser available in different strengths or forms?

A: Microser is provided in the dosage form of an oral tablet. Regulatory dosing instructions confirm that it is available in different strengths, such as 8 mg, 16 mg, or 24 mg tablets, which allows for the adjustment of the total daily dose.

How should Microser be stored and disposed of?

How to Store and Dispose of Microser?

Storage Requirements

To ensure Microser maintains its stability and effectiveness, regulatory documents specify strict storage conditions. The product must be stored below a specific maximum temperature, typically 30 C, and must be protected from light. It is essential to keep this medicine in the original container and ensure the container is tightly closed to protect it from moisture and other environmental factors. The labeled shelf life of the unopened product, when stored correctly, is often documented as three years.

Handling and Disposal

Keep Microser out of the sight and reach of children. Any in-use stability period after the product is prepared (e.g., dilution) is strictly defined (e.g., 48 hours) and depends on using only the specified diluent. Unused, expired, or prepared medicine must be disposed of according to local regulations for pharmaceutical waste, which may classify the product as hazardous or requiring specific cytotoxic handling procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Microser found in:

A-Z Index: